$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

$pirs Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000158364821000034 Filed on August 05, 2021

Income Statement

Concept	2021 Q2	2020 Q2	2020 Q1
Revenue	$3.285M	$11.25M	$13.26M
YoY Change	-70.79%	110.92%	55.19%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.246M	$4.570M	$4.360M
YoY Change	-7.09%	9.07%	-11.56%
% of Gross Profit
Research & Development	$15.80M	$11.33M	$12.76M
YoY Change	39.42%	-15.25%	-10.76%
% of Gross Profit
Depreciation & Amortization	$612.0K	$530.0K	$339.0K
YoY Change	15.47%	1225.0%	104.22%
% of Gross Profit
Operating Expenses	$20.05M	$15.90M	$17.12M
YoY Change	26.07%	-9.46%	-10.98%
Operating Profit	-$16.76M	-$4.655M	-$3.856M
YoY Change	260.06%	-61.94%	-63.91%
Interest Expense	$3.000K	$129.0K	$319.0K
YoY Change	-97.67%	-71.27%	-36.96%
% of Operating Profit
Other Income/Expense, Net	$464.0K	-$424.0K	-$60.00K
YoY Change	-209.43%	-1943.48%	-64.91%
Pretax Income	-$15.50M	-$4.950M	-$3.600M
YoY Change	213.09%	-57.9%	-65.21%
Income Tax
% Of Pretax Income
Net Earnings	-$15.50M	-$5.000M	-$3.600M
YoY Change	210.0%	-57.48%	-65.21%
Net Earnings / Revenue	-471.84%	-44.46%	-27.15%
Basic Earnings Per Share	-$0.25	-$0.09
Diluted Earnings Per Share	-$0.25	-$0.09	-$65.21K
COMMON SHARES
Basic Shares Outstanding	61.91M shares	52.37M shares	55.21M shares
Diluted Shares Outstanding	61.91M shares	52.37M shares

Balance Sheet

Concept	2021 Q2	2020 Q2	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$119.1M	$77.20M	$86.80M
YoY Change	54.27%	-22.57%	-21.66%
Cash & Equivalents	$119.1M	$44.30M	$47.43M
Short-Term Investments		$32.90M	$39.30M
Other Short-Term Assets	$5.773M	$4.100M	$4.300M
YoY Change	40.8%	-10.87%	-32.81%
Inventory
Prepaid Expenses
Receivables	$2.803M	$10.71M	$7.267M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$127.7M	$92.03M	$98.37M
YoY Change	38.73%	-17.44%	-20.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$20.37M	$20.51M	$20.34M
YoY Change	-0.65%	159.96%	315.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.123M	$1.975M	$1.887M
YoY Change	58.13%	-82.81%	-7.04%
Total Long-Term Assets	$27.36M	$25.76M	$25.40M
YoY Change	6.22%	32.91%	34.46%
TOTAL ASSETS
Total Short-Term Assets	$127.7M	$92.03M	$98.37M
Total Long-Term Assets	$27.36M	$25.76M	$25.40M
Total Assets	$155.0M	$117.8M	$123.8M
YoY Change	31.62%	-9.98%	-13.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.310M	$4.406M	$3.500M
YoY Change	-47.57%	9.3%	-6.12%
Accrued Expenses	$16.08M	$5.942M	$6.939M
YoY Change	170.67%	-30.02%	-24.71%
Deferred Revenue	$25.54M	$7.912M	$10.04M
YoY Change	222.75%	-72.15%	-64.36%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$43.93M	$18.26M	$20.48M
YoY Change	140.57%	-55.39%	-50.19%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$52.90M	$53.50M
YoY Change	-100.0%	329.49%	198048.15%
Total Long-Term Liabilities	$0.00	$52.90M	$53.50M
YoY Change	-100.0%	329.49%	198048.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$43.93M	$18.26M	$20.48M
Total Long-Term Liabilities	$0.00	$52.90M	$53.50M
Total Liabilities	$108.3M	$71.11M	$73.97M
YoY Change	52.31%	-36.14%	-29.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$231.1M	-$182.7M	-$177.8M
YoY Change	26.48%	6.97%	19.55%
Common Stock	$277.6M	$230.5M	$228.8M
YoY Change	20.44%	19.41%	19.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$46.72M	$46.67M	$49.81M
YoY Change
Total Liabilities & Shareholders Equity	$155.0M	$117.8M	$123.8M
YoY Change	31.62%	-9.98%	-13.55%

Cashflow Statement

Concept	2021 Q2	2020 Q2	2020 Q1
OPERATING ACTIVITIES
Net Income	-$15.50M	-$5.000M	-$3.600M
YoY Change	210.0%	-57.48%	-65.21%
Depreciation, Depletion And Amortization	$612.0K	$530.0K	$339.0K
YoY Change	15.47%	1225.0%	104.22%
Cash From Operating Activities	$29.91M	-$9.780M	-$15.13M
YoY Change	-405.81%	-8.85%	0.15%
INVESTING ACTIVITIES
Capital Expenditures	-$227.0K	-$1.060M	$1.927M
YoY Change	-78.58%	13.98%	1492.56%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$6.660M	$2.340M
YoY Change	-100.0%	-51.91%	-145.0%
Cash From Investing Activities	-$227.0K	$5.600M	$414.0K
YoY Change	-104.05%	-56.66%	-107.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	22.62M	420.0K	$0.00
YoY Change	5285.71%	50.0%
NET CHANGE
Cash From Operating Activities	29.91M	-9.780M	-$15.13M
Cash From Investing Activities	-227.0K	5.600M	$414.0K
Cash From Financing Activities	22.62M	420.0K	$0.00
Net Change In Cash	52.30M	-3.760M	-$14.83M
YoY Change	-1490.98%	-252.23%	-34.88%
FREE CASH FLOW
Cash From Operating Activities	$29.91M	-$9.780M	-$15.13M
Capital Expenditures	-$227.0K	-$1.060M	$1.927M
Free Cash Flow	$30.14M	-$8.720M	-$17.06M
YoY Change	-445.58%	-11.02%	12.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001583648
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37471
	dei	Entity Registrant Name EntityRegistrantName	PIERIS PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-0784346
	dei	Entity Address Address Line1 EntityAddressAddressLine1	255 State Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	9th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Country EntityAddressCountry	US
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02109
	dei	City Area Code CityAreaCode	857
	dei	Local Phone Number LocalPhoneNumber	246-8998
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	PIRS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	66710712	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	119097000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70436000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2803000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1706000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5773000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3579000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	127673000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	75721000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20373000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22046000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3861000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3934000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3123000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3309000	USD
CY2021Q2	us-gaap	Assets Assets	155030000	USD
CY2020Q4	us-gaap	Assets Assets	105010000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2310000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1787000	USD
CY2021Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	16082000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7731000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25536000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12627000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	43928000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22145000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	49421000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	35900000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14960000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15932000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	108309000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	73983000	USD
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	67000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	56000	USD
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	277496000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	242672000	USD
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	234000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-295000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-231076000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-211406000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	46721000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	31027000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	155030000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	105010000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2540000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10930000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17406000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	19815000	USD
CY2021Q2	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	745000	USD
CY2020Q2	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	316000	USD
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	1512000	USD
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	4692000	USD
CY2021Q2	us-gaap	Revenues Revenues	3285000	USD
CY2020Q2	us-gaap	Revenues Revenues	11246000	USD
	us-gaap	Revenues Revenues	18918000	USD
	us-gaap	Revenues Revenues	24507000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15800000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11333000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32362000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24091000	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4246000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4568000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8376000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8927000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	20046000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	15901000	USD
	us-gaap	Operating Expenses OperatingExpenses	40738000	USD
	us-gaap	Operating Expenses OperatingExpenses	33018000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16761000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4655000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21820000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8511000	USD
CY2021Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3000	USD
CY2020Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	129000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	6000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	448000	USD
CY2021Q2	pirs	Revenue Not From Contract With Customer Grant Income RevenueNotFromContractWithCustomerGrantIncome	796000	USD
CY2020Q2	pirs	Revenue Not From Contract With Customer Grant Income RevenueNotFromContractWithCustomerGrantIncome	0	USD
	pirs	Revenue Not From Contract With Customer Grant Income RevenueNotFromContractWithCustomerGrantIncome	796000	USD
	pirs	Revenue Not From Contract With Customer Grant Income RevenueNotFromContractWithCustomerGrantIncome	0	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	464000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-424000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1348000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-484000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-15498000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-4950000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-19670000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8547000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	40000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	178000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	529000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	830000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-15000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	101000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15458000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4787000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19141000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7616000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61905000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61905000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52371000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52371000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59116000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59116000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53792000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53792000	shares
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	49806000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-4950000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	178000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-15000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1237000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	271000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	145000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	46672000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	38236000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-15498000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	40000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1326000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	272000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	96000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	837000	USD
CY2021Q2	pirs	Stock Issued During Period Value Conversion Of Preferred Stock StockIssuedDuringPeriodValueConversionOfPreferredStock	0	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	46721000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	51352000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8547000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	830000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	101000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	271000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	145000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-19670000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	46672000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	31027000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2520000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	529000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2525000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	292000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	96000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	837000	USD
	pirs	Stock Issued During Period Value Conversion Of Preferred Stock StockIssuedDuringPeriodValueConversionOfPreferredStock	0	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	46721000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-19670000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8547000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1242000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	869000	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	-48000	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	156000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2525000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2520000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	14000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-343000	USD
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-33733000	USD
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	20250000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	17768000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24909000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	257000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2988000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	47523000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	38525000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-257000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6010000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	292000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	271000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	837000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	96000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	145000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	18913000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	400000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12172000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32310000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	416000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1160000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	525000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	48661000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17958000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44302000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70436000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62260000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	119097000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	31000	USD
	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	0	USD
	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	329000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	119100000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-15500000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-5000000.0	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-231100000	USD
	us-gaap	Use Of Estimates UseOfEstimates	The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; determination of the incremental borrowing rate to calculate right-of-use assets and lease liabilities; beneficial conversion features; fair value of stock options, preferred stock, and warrants; and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	The Company has no financial instruments with off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company’s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does not obtain collateral.
CY2021Q2	us-gaap	Revenues Revenues	3285000	USD
CY2020Q2	us-gaap	Revenues Revenues	11246000	USD
	us-gaap	Revenues Revenues	18918000	USD
	us-gaap	Revenues Revenues	24507000	USD
CY2017Q2	pirs	Number Of Technology Licenses NumberOfTechnologyLicenses	5	leaseAgreement
CY2017Q1	pirs	Number Of Separate Performance Obligations NumberOfSeparatePerformanceObligations	1	performanceObligation
CY2021Q2	pirs	Additions To Contract With Customer Liability AdditionsToContractWithCustomerLiability	26100000	USD
	pirs	Additions To Contract With Customer Liability AdditionsToContractWithCustomerLiability	30100000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	700000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1500000	USD
CY2021Q2	us-gaap	Grants Receivable GrantsReceivable	14200000	EUR
CY2021Q2	us-gaap	Grants Receivable GrantsReceivable	17000000.0	USD
CY2021Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	91800000	USD
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	64000000.0	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	200000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	27232000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	27861000	USD
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6859000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5815000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20373000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22046000	USD
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4215000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1220000	USD
CY2021Q2	pirs	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	3830000	USD
CY2020Q4	pirs	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	0	USD
CY2021Q2	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	2813000	USD
CY2020Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	2001000	USD
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2251000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2759000	USD
CY2021Q2	pirs	Accrued License Obligations Current AccruedLicenseObligationsCurrent	1653000	USD
CY2020Q4	pirs	Accrued License Obligations Current AccruedLicenseObligationsCurrent	358000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	959000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1030000	USD
CY2021Q2	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	189000	USD
CY2020Q4	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	128000	USD
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	173000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	235000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16083000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7731000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	36500000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	37300000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	66679223	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	66679223	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56002815	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56002815	shares
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15617	shares
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15617	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	14429	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	14429	shares
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	379000	USD
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	347000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	744000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	751000	USD
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	181000	USD
CY2020Q2	us-gaap	Variable Lease Cost VariableLeaseCost	156000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	364000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	344000	USD
CY2021Q2	us-gaap	Lease Cost LeaseCost	560000	USD
CY2020Q2	us-gaap	Lease Cost LeaseCost	503000	USD
	us-gaap	Lease Cost LeaseCost	1108000	USD
	us-gaap	Lease Cost LeaseCost	1095000	USD
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	600000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	1300000	USD
CY2020Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	600000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	900000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1283000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2380000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2346000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2346000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2346000	USD
CY2021Q2	pirs	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	15443000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	26144000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10224000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	15920000	USD

Files In Submission

Name	View Source	Status
0001583648-21-000034-index-headers.html	Edgar Link	pending
0001583648-21-000034-index.html	Edgar Link	pending
0001583648-21-000034.txt	Edgar Link	pending
0001583648-21-000034-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pieris-bpexclusiveproduc.htm	Edgar Link	pending
pieris-bpexclusiveproduc001.jpg	Edgar Link	pending
pieris-bpexclusiveproduc002.jpg	Edgar Link	pending
pieris-bpexclusiveproduc003.jpg	Edgar Link	pending
pieris-bpexclusiveproduc004.jpg	Edgar Link	pending
pieris-bpexclusiveproduc005.jpg	Edgar Link	pending
pieris-bpexclusiveproduc006.jpg	Edgar Link	pending
pieris-bpexclusiveproduc007.jpg	Edgar Link	pending
pieris-bpexclusiveproduc008.jpg	Edgar Link	pending
pieris-bpexclusiveproduc009.jpg	Edgar Link	pending
pieris-bpexclusiveproduc010.jpg	Edgar Link	pending
pieris-bpexclusiveproduc011.jpg	Edgar Link	pending
pieris-bpexclusiveproduc012.jpg	Edgar Link	pending
pieris-bpexclusiveproduc013.jpg	Edgar Link	pending
pieris-bpexclusiveproduc014.jpg	Edgar Link	pending
pieris-bpexclusiveproduc015.jpg	Edgar Link	pending
pieris-bpexclusiveproduc016.jpg	Edgar Link	pending
pieris-bpexclusiveproduc017.jpg	Edgar Link	pending
pieris-bpexclusiveproduc018.jpg	Edgar Link	pending
pieris-bpexclusiveproduc019.jpg	Edgar Link	pending
pieris-bpexclusiveproduc020.jpg	Edgar Link	pending
pieris-bpexclusiveproduc021.jpg	Edgar Link	pending
pieris-bpexclusiveproduc022.jpg	Edgar Link	pending
pieris-bpexclusiveproduc023.jpg	Edgar Link	pending
pieris-bpexclusiveproduc024.jpg	Edgar Link	pending
pieris-bpexclusiveproduc025.jpg	Edgar Link	pending
pieris-bpexclusiveproduc026.jpg	Edgar Link	pending
pieris-bpexclusiveproduc027.jpg	Edgar Link	pending
pieris-bpexclusiveproduc028.jpg	Edgar Link	pending
pieris-bpexclusiveproduc029.jpg	Edgar Link	pending
pieris-bpexclusiveproduc030.jpg	Edgar Link	pending
pieris-bpexclusiveproduc031.jpg	Edgar Link	pending
pieris-bpexclusiveproduc032.jpg	Edgar Link	pending
pieris-bpexclusiveproduc033.jpg	Edgar Link	pending
pieris-bpexclusiveproduc034.jpg	Edgar Link	pending
pieris-bpexclusiveproduc035.jpg	Edgar Link	pending
pieris-bpexclusiveproduc036.jpg	Edgar Link	pending
pieris-bpexclusiveproduc037.jpg	Edgar Link	pending
pieris-bpexclusiveproduc038.jpg	Edgar Link	pending
pieris-bpexclusiveproduc039.jpg	Edgar Link	pending
pieris-bpexclusiveproduc040.jpg	Edgar Link	pending
pieris-bpexclusiveproduc041.jpg	Edgar Link	pending
pieris-bpexclusiveproduc042.jpg	Edgar Link	pending
pieris-bpexclusiveproduc043.jpg	Edgar Link	pending
pieris-bpexclusiveproduc044.jpg	Edgar Link	pending
pieris-bpexclusiveproduc045.jpg	Edgar Link	pending
pieris-bpexclusiveproduc046.jpg	Edgar Link	pending
pieris-bpexclusiveproduc047.jpg	Edgar Link	pending
pieris-bpexclusiveproduc048.jpg	Edgar Link	pending
pieris-bpexclusiveproduc049.jpg	Edgar Link	pending
pieris-bpexclusiveproduc050.jpg	Edgar Link	pending
pieris-bpexclusiveproduc051.jpg	Edgar Link	pending
pieris-bpexclusiveproduc052.jpg	Edgar Link	pending
pieris-bpexclusiveproduc053.jpg	Edgar Link	pending
pieris-bpexclusiveproduc054.jpg	Edgar Link	pending
pieris-bpexclusiveproduc055.jpg	Edgar Link	pending
pieris-bpexclusiveproduc056.jpg	Edgar Link	pending
pieris-bpexclusiveproduc057.jpg	Edgar Link	pending
pieris-bpexclusiveproduc058.jpg	Edgar Link	pending
pieris-bpexclusiveproduc059.jpg	Edgar Link	pending
pieris-bpexclusiveproduc060.jpg	Edgar Link	pending
pieris-bpexclusiveproduc061.jpg	Edgar Link	pending
pieris-bpexclusiveproduc062.jpg	Edgar Link	pending
pieris-bpexclusiveproduc063.jpg	Edgar Link	pending
pieris-bpexclusiveproduc064.jpg	Edgar Link	pending
pieris-bpexclusiveproduc065.jpg	Edgar Link	pending
pieris-bpexclusiveproduc066.jpg	Edgar Link	pending
pieris-bpexclusiveproduc067.jpg	Edgar Link	pending
pieris-bpexclusiveproduc068.jpg	Edgar Link	pending
pieris-bpexclusiveproduc069.jpg	Edgar Link	pending
pieris-bpexclusiveproduc070.jpg	Edgar Link	pending
pieris-bpexclusiveproduc071.jpg	Edgar Link	pending
pieris-bpexclusiveproduc072.jpg	Edgar Link	pending
pieris-bpexclusiveproduc073.jpg	Edgar Link	pending
pieris-bpexclusiveproduc074.jpg	Edgar Link	pending
pieris-bpexclusiveproduc075.jpg	Edgar Link	pending
pieris-bpexclusiveproduc076.jpg	Edgar Link	pending
pieris-bpexclusiveproduc077.jpg	Edgar Link	pending
pieris-bpexclusiveproduc078.jpg	Edgar Link	pending
pieris-bpexclusiveproduc079.jpg	Edgar Link	pending
pieris-bpexclusiveproduc080.jpg	Edgar Link	pending
pieris-bpexclusiveproduc081.jpg	Edgar Link	pending
pieris-bpexclusiveproduc082.jpg	Edgar Link	pending
pieris-bpexclusiveproduc083.jpg	Edgar Link	pending
pieris-bpexclusiveproduc084.jpg	Edgar Link	pending
pieris-bpexclusiveproduc085.jpg	Edgar Link	pending
pieris-bpexclusiveproduc086.jpg	Edgar Link	pending
pieris-bpexclusiveproduc087.jpg	Edgar Link	pending
pieris-bpexclusiveproduc088.jpg	Edgar Link	pending
pieris-bpexclusiveproduc089.jpg	Edgar Link	pending
pieris-bpexclusiveproduc090.jpg	Edgar Link	pending
pieris-bpexclusiveproduc091.jpg	Edgar Link	pending
pieris-bpexclusiveproduc092.jpg	Edgar Link	pending
pieris-bpexclusiveproduc093.jpg	Edgar Link	pending
pieris-bpexclusiveproduc094.jpg	Edgar Link	pending
pieris-genentechcollabor.htm	Edgar Link	pending
pieris-genentechcollabor001.jpg	Edgar Link	pending
pieris-genentechcollabor002.jpg	Edgar Link	pending
pieris-genentechcollabor003.jpg	Edgar Link	pending
pieris-genentechcollabor004.jpg	Edgar Link	pending
pieris-genentechcollabor005.jpg	Edgar Link	pending
pieris-genentechcollabor006.jpg	Edgar Link	pending
pieris-genentechcollabor007.jpg	Edgar Link	pending
pieris-genentechcollabor008.jpg	Edgar Link	pending
pieris-genentechcollabor009.jpg	Edgar Link	pending
pieris-genentechcollabor010.jpg	Edgar Link	pending
pieris-genentechcollabor011.jpg	Edgar Link	pending
pieris-genentechcollabor012.jpg	Edgar Link	pending
pieris-genentechcollabor013.jpg	Edgar Link	pending
pieris-genentechcollabor014.jpg	Edgar Link	pending
pieris-genentechcollabor015.jpg	Edgar Link	pending
pieris-genentechcollabor016.jpg	Edgar Link	pending
pieris-genentechcollabor017.jpg	Edgar Link	pending
pieris-genentechcollabor018.jpg	Edgar Link	pending
pieris-genentechcollabor019.jpg	Edgar Link	pending
pieris-genentechcollabor020.jpg	Edgar Link	pending
pieris-genentechcollabor021.jpg	Edgar Link	pending
pieris-genentechcollabor022.jpg	Edgar Link	pending
pieris-genentechcollabor023.jpg	Edgar Link	pending
pieris-genentechcollabor024.jpg	Edgar Link	pending
pieris-genentechcollabor025.jpg	Edgar Link	pending
pieris-genentechcollabor026.jpg	Edgar Link	pending
pieris-genentechcollabor027.jpg	Edgar Link	pending
pieris-genentechcollabor028.jpg	Edgar Link	pending
pieris-genentechcollabor029.jpg	Edgar Link	pending
pieris-genentechcollabor030.jpg	Edgar Link	pending
pieris-genentechcollabor031.jpg	Edgar Link	pending
pieris-genentechcollabor032.jpg	Edgar Link	pending
pieris-genentechcollabor033.jpg	Edgar Link	pending
pieris-genentechcollabor034.jpg	Edgar Link	pending
pieris-genentechcollabor035.jpg	Edgar Link	pending
pieris-genentechcollabor036.jpg	Edgar Link	pending
pieris-genentechcollabor037.jpg	Edgar Link	pending
pieris-genentechcollabor038.jpg	Edgar Link	pending
pieris-genentechcollabor039.jpg	Edgar Link	pending
pieris-genentechcollabor040.jpg	Edgar Link	pending
pieris-genentechcollabor041.jpg	Edgar Link	pending
pieris-genentechcollabor042.jpg	Edgar Link	pending
pieris-genentechcollabor043.jpg	Edgar Link	pending
pieris-genentechcollabor044.jpg	Edgar Link	pending
pieris-genentechcollabor045.jpg	Edgar Link	pending
pieris-genentechcollabor046.jpg	Edgar Link	pending
pieris-genentechcollabor047.jpg	Edgar Link	pending
pieris-genentechcollabor048.jpg	Edgar Link	pending
pieris-genentechcollabor049.jpg	Edgar Link	pending
pieris-genentechcollabor050.jpg	Edgar Link	pending
pieris-genentechcollabor051.jpg	Edgar Link	pending
pieris-genentechcollabor052.jpg	Edgar Link	pending
pieris-genentechcollabor053.jpg	Edgar Link	pending
pieris-genentechcollabor054.jpg	Edgar Link	pending
pieris-genentechcollabor055.jpg	Edgar Link	pending
pieris-genentechcollabor056.jpg	Edgar Link	pending
pieris-genentechcollabor057.jpg	Edgar Link	pending
pieris-genentechcollabor058.jpg	Edgar Link	pending
pieris-genentechcollabor059.jpg	Edgar Link	pending
pieris-genentechcollabor060.jpg	Edgar Link	pending
pieris-genentechcollabor061.jpg	Edgar Link	pending
pieris-genentechcollabor062.jpg	Edgar Link	pending
pirs-20210630.htm	Edgar Link	pending
pirs-20210630.xsd	Edgar Link	pending
pirs-20210630_cal.xml	Edgar Link	unprocessable
pirs-20210630_def.xml	Edgar Link	unprocessable
pirs-20210630_htm.xml	Edgar Link	completed
pirs-20210630_lab.xml	Edgar Link	unprocessable
pirs-20210630_pre.xml	Edgar Link	unprocessable
pirs6-30x21ex311.htm	Edgar Link	pending
pirs6-30x21ex312.htm	Edgar Link	pending
pirs6-30x21ex321.htm	Edgar Link	pending
pirs6-30x21ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

2021 Q2 Form 10-Q Financial Statement

#000158364821000034 Filed on August 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS PIERIS PHARMACEUTICALS, INC. Stock $pirs

2021 Q2 Form 10-Q Financial Statement

#000158364821000034 Filed on August 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs